http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
Progress in Medicinal Chemistry, Volume 59 provides a review of eclectic developments in medicinal G139 chemistry. Each chapter is written by an international board of authors, with this release focusing on Small Molecules - Giant Leaps for Immuno-Oncology, Reviewing P2X7, Reviewing ASK1, and Reviewing DNA-encoded libraries. Provides extended, timely reviews of topics in medicinal chemistry Contains targets and technologies relevant to the discovery of tomorrow's drugs Presents analyses of successful drug discovery programs.
Chapter Two: P2X7 receptor antagonists for the treatment of systemic inflammatory disorders -- 1. Introduction: P2X7 and inflammatory disorders -- 2. P2X7R antagonists in clinical trials -- 2.1. P2X7R antagonists in clinical trials for mood disorders -- 2.2. P2X7R antagonists in clinical trials for non-alcoholic steatohepatitis (NASH) -- 3. P2X7 receptor antagonists -- 3.1. Acyclic carboxamides -- 3.2. Heteroaromatic carboxamide cores -- 4. P2X7 PET ligands -- 5. Conclusion -- Acknowledgements -- References -- Further reading -- Chapter Three: Discovery and development of ASK1 inhibitors
1. Introduction -- 2. Structure and regulation -- 2.1. Events downstream of ASK1 -- 2.2. Key factors interacting with ASK1 and composing the ASK1 signalosome -- 2.3. Key events regulating ASK1 activity -- 3. Cellular functions -- 3.1. Cell death -- 3.2. Inflammation -- 4. Involvement in disease -- 4.1. Neurodegenerative disorders -- 4.1.1. Alzheimerś disease -- 4.1.2. Parkinsonś disease -- 4.1.3. Huntingtonś disease -- 4.1.4. Amyotrophic lateral sclerosis -- 4.2. Cardiovascular diseases -- 4.3. Diabetes -- 4.4. Autoimmune and inflammatory diseases -- 4.4.1. Multiple sclerosis
4.4.2. Rheumatoid arthritis -- 4.5. Osteoarthritis -- 4.5.1. Chronic pain -- 4.6. The role of ASK1 in liver diseases -- 4.7. The role of ASK1 in kidney diseases -- 4.8. The role of ASK1 in cancer -- 4.8.1. Functional studies demonstrating the role of ASK1 as a tumour suppressor -- 4.8.2. Functional studies demonstrating the role of ASK1 as oncogene -- 5. Discovery of small molecule ASK1 inhibitors -- 5.1. Introduction -- 5.2. Gilead sciences -- 5.3. Convergence/Galapagos -- 5.4. Eli Lilly -- 5.5. Enanta -- 5.6. Fronthera -- 5.7. Hepagene therapeutics
Description based upon print version of record.
5.8. Institute of molecular biology and genetics, Kiev